Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2019 · 10-Q
Revenue$8.08B$8.08B+5.5% vs Q3 2018 Net Income$960.00M$960.00M+70.5% vs Q3 2018 EPS Diluted$0.53$0.53+65.6% vs Q3 2018 Gross Profit$4,234,000,000+7.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,948,000,000−10.8% Free Cash Flowderived$1,547,000,000−15.4% Margins · derivedGross margin52.4%+0.9 pt vs Q3 2018
Operating margin14.8%+1.8 pt vs Q3 2018
Net margin11.9%+4.5 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 31, 2019 · 31 d after period end